| Literature DB >> 30486484 |
Sandeep B Subramanya1, Balaji Venkataraman2, Mohamed Fizur Nagoor Meeran3, Sameer N Goyal4,5, Chandragouda R Patil6, Shreesh Ojha7.
Abstract
Acetaminophen (APAP), which is also known as paracetamol or N-acetyl-p-aminophenol is a safe and potent drug for fever, pain and inflammation when used at its normal therapeutic doses. It is available as over-the-counter drug and used by all the age groups. The overdose results in acute liver failure that often requires liver transplantation. Current clinical therapy for APAP-induced liver toxicity is the administration of N-acetyl-cysteine (NAC), a sulphydryl compound an approved drug which acts by replenishing cellular glutathione (GSH) stores in the liver. Over the past five decades, several studies indicate that the safety and efficacy of herbal extracts or plant derived compounds that are used either as monotherapy or as an adjunct therapy along with conventional medicines for hepatotoxicity have shown favorable responses. Phytochemicals mitigate necrotic cell death and protect against APAP-induced liver toxicityby restoring cellular antioxidant defense system, limiting oxidative stress and subsequently protecting mitochondrial dysfunction and inflammation. Recent experimental evidences indicat that these phytochemicals also regulate differential gene expression to modulate various cellular pathways that are implicated in cellular protection. Therefore, in this review, we highlight the role of the phytochemicals, which are shown to be efficacious in clinically relevant APAP-induced hepatotoxicity experimental models. In this review, we have made comprehensive attempt to delineate the molecular mechanism and the cellular targets that are modulated by the phytochemicals to mediate the cytoprotective effect against APAP-induced hepatotoxicity. In this review, we have also defined the challenges and scope of phytochemicals to be developed as drugs to target APAP-induced hepatotoxicity.Entities:
Keywords: APAP; acetaminophen; animals; hepatotoxicity; hpatoprotection; natural products; paracetamol; phytochemicals; plants; preclinical studies; small molecules
Mesh:
Substances:
Year: 2018 PMID: 30486484 PMCID: PMC6321362 DOI: 10.3390/ijms19123776
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Schematic representation of phytochemical attenuate acetaminophen-induced liver toxicity.
Phytochemicals showed hepatoprotective effect in the mice model of acetaminophen-induced liver toxicity.
| Phytochemical | Dose of Phytochemical | Dose of APAP and Route | Efficacy and Major Mechanisms | CYP2E1 Inhibition | References |
|---|---|---|---|---|---|
| Acanthoic acid | 50, 100 mg/kg, | 300 mg/kg, | LFT, antioxidants, anti-inflammatory, antiapoptotic and antinecrotic | No | [ |
| Ajoene | 20,50,100 mg/kg, | 300 mg/kg, | LFT, GSH | No | [ |
| Apigenin | 100, 200 mg/kg | 350 mg/kg, | LFT, antioxidants, H&E | No | [ |
| Astaxanthin | 30, 60 mg/kg, | 300 mg/kg, | LFT, antioxidants, pro-inflammatory cytokines, inhibition of JNK signal pathway and phosphorylation of ERK and P38 | No | [ |
| Baicalin | 15, 30, 60 mg/kg, | 300 mg/kg, | LFT, cytokines, H&E, decrease hepatic phosphorylated extracellular signal-regulated kinase expression | No | [ |
| Berberine | 1 or 5 mg/kg, | 500 mg/kg, | LFT, mortality, NLRP3 inflammasome pathway | No | [ |
| Boswellic acid | 0.05, 0.1% in diet × 4 weeks | 400 mg/kg, | LFT, antioxidants, cytokines and chemokines, toll-like receptor signaling and H&E | Yes | [ |
| Carnosic acid | 100 mg/kg × 3 days | 400 mg/kg, | LFT, antioxidants, Nrf2/Keap pathway, H&E | No | [ |
| Chlorogenic acid | 5, 10, 20 or 40 mg/kg × 7days | 300 mg/kg, | LFT, antioxidants, antiapoptotic, ERK1/2, JNK, p38 kinases mediated MAPK pathway | No | [ |
| Chlorogenic acid | 10, 20, 40 mg/kg at 1h after given AP | 400 mg/kg, and another 3h later | LFT, MPO, H&E, pro-inflamatory cytokines, chemokines, TLR3/4 and NFκB signaling | No | [ |
| Corynoline, acetylcorynoline and protopine | 50, 100 mg/kg, 8 to 24 h before APAP | - | LFT, antioxidants | Yes | [ |
| Esculentoside A | 2.5 mg/kg, | 400, 900 mg/kg, | LFT, antioxidants, H&E, increases Nrf2 expression and phosphorylation of AMPK, Akt and GSK3β | No | [ |
| Ferulic acid | 30, 100 mg/kg, | 350 mg/kg, | LFT, antioxidants, H&E, MAPK and TLR4 pathway | Yes | [ |
| Gallic acid | 100 mg/kg, | 900 mg/kg, | LFT, pro-inflammatory cytokines, antioxidants | No | [ |
| 6-Gingerol | 30 mg/kg, 30 min after APAP | 900 mg/kg | LFT, antioxidants, comparable to the standard drug silymarin | No | [ |
| Glycyrrhetinic acid | 500 mg/kg × 20 days before APAP | 400 mg/kg, | LFT, metabolism pathway of fatty acids, palmtioylcarnitine and oleoylcarnitine | No | [ |
| Glycyrrhizin | Oral, | 200-600 mg/kg, | LFT, antioxidants, pro-inflammatory cytokines, antiapptotic, H & E, only | Yes | [ |
| Hyperoside | 10, 50, 100 mg/kg, | 300 mg/kg, | LFT, antioxidants, Nrf2/Keap pathway, Phase II enzymes | Yes | [ |
| Isoquercitrin | 10, 20, or 50 mg/kg, | 300 mg/kg, | LFT, Pro-inflammatory cytokines, antioxidants, NF-κB/MAPK pathway | Yes | [ |
| Kaempferoll8-C-β-galactoside and C-glycoside | 25, 50, 75 mg/kg | 500 mg/kg | LFT, H&E, comparable to silymarin | No | [ |
| Luteolin and quercetin 3-β-d-glucoside | 200, 400 mg/kg, | 2 g/kg, | LFT, antioxidants, H&E | No | [ |
| Lycopene | 10, 100mg/kg, | 500 mg/kg, | LFT, antioxidants, MMP-2, H&E, morphometry | No | [ |
| Naringenin | 200, 400, and 800 mg/kg, | 250 mg/kg, | LFT, antioxidants, H&E | No | [ |
| Paeonol | 25, 50, 100 mg/kg, | 400 mg/kg, | LFT, antioxidants, chemokines and cytokines, JNK pathways | No | [ |
| Fulvotomentosides, oleanolic acid, total saponins of | - | - | LFT, H&E, Fulvomentosides found most potent, oleanic acid, total saponins of | No | [ |
| α-Hederin and sapindoside B | 20 mg/kg, | - | LFT, H&E, mortality | No | [ |
| Procyanidins | 1 or 10 mg/kg, | 300 mg/kg, | LFT, enhanced Nrf2/ARE activity and phase II detoxifying/antioxidant enzymes | Yes | [ |
| Rutin | 20 mg/kg, | 640 mg/kg, | LFT, antioxidants | No | [ |
| Sodium ferulate | 100 mg/kg, | 130 mg/kg, | LFT, antioxidants | No | [ |
| Salidroside | 50, 100 mg/kg 2 h before APAP | 300 mg/kg, | LFT, pro-inflammatory cytokines, antioxidants, antiapoptotic, H&E, parallel with NAC | No | [ |
| Salvianolic acid B | 25 and 50 mg/kg, | 300 mg/kg, | LFT, antioxidants, Nrf2, HO-1 and Gclc activation of the PI3K and PKC pathways | Yes | [ |
| Sauchinone | 6 h after APAP | 500 mg/kg, | LFT, antioxidants, H&E, Keap1/Nrf2 and GSK3β-PKCδ pathway | No | [ |
| Schisandrol B | 200 mg/kg, | 400 mg/kg, | LFT, H&E, antioxidants, Nrf2/ARE signaling pathway | No | [ |
| Schisandrol B | 6.25, 25 and 100 mg/kg for 7 days before APAP | 400 mg/kg, | LFT, antioxidants, antiapoptotic (p53, p21, CCND1, PCNA, and BCL-2) | Yes | [ |
| Schisandrin derivatives | 200 mg/kg/day, | 400 mg/kg, | LFT, antioxidants, H&E | Yes | [ |
| Silipide | 400 mg/kg, | - | LFT, antioxidant activities | No | [ |
| Quercitrin | 10, 50 mg/kg, | 300 mg/kg, | LFT, antioxidants and Nrf2/ARE, anti-inflammatory, MAPK pathways including ERK, JNK, and p38 MAPK, comparable to silymarin | No | [ |
| Tannic acid | 25, 50 mg/kg, | 400 mg/kg, | LFT, antioxidants, pro-inflammatory cytokines, H&E, suppressed c-Fos, c-Jun, NF-κB (p65) and caspase-3, regulated Bax/Bcl-2, Nrf2 and HO-1 | No | [ |
| Trans-anethole | 62.5, 125, 250 mg/kg, | 250 mg/kg, | LFT, antioxidants, pro-inflammatory cytokines, morphometrics, H&E | No | [ |
| Withaferin A | 7 mg/kg, | 250 mg/kg, | LFT, Keap1-independent & Pten/PI3K/Akt-dependent | No | [ |
Phytochemicals showed hepatoprotective effect in the rat model of acetaminophen-induced liver injury.
| Phytochemical | Dose of Phytochemical | Route and Dose of APAP | Efficacy and Major Mechanisms | CYP2E1 Inhibition | References |
|---|---|---|---|---|---|
| Andrographolide | 200 mg/kg, | 3 g/kg, | LFT, H&E, antioxidants | No | [ |
| Berberine | 4 mg/kg; | - | LFT, antioxidants | Yes | [ |
| Chlorogenic acid | 40 mg/kg | 300 mg/kg, intragastric | LFT, antioxidants LFT, antioxidants | Yes | [ |
| Esculetin | 6 mg/kg | 640 mg/kg, | LFT, antioxidants | No | [ |
| Gomisin A | 50 mg/kg | 750 mg/kg | LFT, antioxidants, antiapoptotic, H&E | No | [ |
| Hesperidin | 100, 200 mg/kg × 14 days | 750 mg/kg, | LFT, antioxidants, antioapoptotic, H&E | No | [ |
| Liquiritigenin & Schisandrin C derivative | LFT, H & E, liquiritigenin and combination showed protection while schisandrin C derivative failed | No | [ | ||
| Lupeol | 150 mg/kg, | 1 g/kg | LFT, antioxidants, antiapoptotic, H&E | No | [ |
| Magnolol | 0.01, 0.1, 1 µg/kg 0.5 h after APAP | 500 mg/kg, | LFT, H&E, antioxidants | No | [ |
| Pterostilbene | 50, 100 mg/kg, | 800 mg/kg, | LFT, lipid profiles, pro-inflammatory cytokines, antioxidants, antiapoptotitic, antifibrotic, comparable to silymarin | No | [ |
| Punicalagin and Punicalin | 1,5,12.5 or 25 mg/kg, | 500 mg/kg, | LFT, antioxidants, H&E | No | [ |
| Rutin | 20 mg/kg, | 500 mg/kg | LFT, H&E, TEM, antioxidants, comparable to silymarin | No | [ |
| Saponarin | 80 mg/kg, | 600 mg/kg, | LFT, antioxidants, H&E | Yes | [ |
| Silybin | - | - | LFT, GSH and lipid peroxidation | No | [ |
| Syringic acid | 25, 50 and 100 mg/kg | 750 mg/kg | LFT, H&E, comparable to silymarin | No | [ |
Phytochemicals showed hepatoprotective effect in the in vitro model of acetaminophen-induced liver injury.
| Phytochemicals | Dose of Phytochemical | Cells and Dose of APAP | Efficacy and Major Mechanisms | CYP2E1 Inhibition | References |
|---|---|---|---|---|---|
| Andrographolide | 0.75–12 mg/kg | Rat hepatocytes | LFT, viability, more potent than silymarin | No | [ |
| Lupeol | 10 μM | Rat hepatocytes, APAP (675 μM) | Maintaining redox and preventing mitochondria-mediated apoptosis | No | [ |
| Paeonol | 20, 40, 80 μM | Mouse hepatocytes H2O2 or APAP | LDH, ROS and pro-inflammatory genes and reduced IKKα/β, IκBα and p65 phosphorylation | No | [ |
| Silibin | 25 μM | Rat hepatocytes, APAP (25–30 mM) | Inhibited APAP toxicity, prevented DNA strand breaks formation | No | [ |
| CalamusinsA-I | 10 μM | HepG2 cells | Weak hepatoprotective activities against APAP | No | [ |
| α-Hederin | 10, 30 µM/kg, | Rat liver microsomes | Dose-dependent suppression of liver cytochrome P450 enzymes | Yes | [ |
| Saponarin | 60-0.006 μg/mL | Rat hepatocytes, APAP (100 μM) | Cell viability, LDH, GSH, MDA | Yes | [ |
| Chlorogenic acid | 1, 10, 25, 50 and 100 μM/L | L-02 cells | LFT, cell viability | Yes | [ |
| Procyanidins | 10, 25 and 50 μg/L | HepG2 cells | Enhanced phase II detoxifying and antioxidant enzymes and Nrf2/ARE activity | Yes | [ |
| Thymol and carvacrol | 25, 50 and 100 µM | HepG2 cells | Antioxidants, pro-inflammatory cytokines, comparable to NAC | No | [ |
The medicinal plants showed to ameliorate the acetaminophen-induced hepatotoxicity in different models.
| Plant Names | Plant Names | Plant Names | Plant Names | Plant Names |
|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
|
The polyherbal or single herb formulations showed protective against APAP-induced liver toxicity.
| S. No. | Polyherbal/Single HerbFormulation |
|---|---|
| 1 | 999 Ganmaoling® |
| 2 | A formulation of |
| 3 | A polyherbal formulation containing eight herbs; Vasaguduchyadi Kwatha® |
| 4 | A polyherbal formulation containing a mixture of leaves of |
| 5 | A polyherbal formulation containing aqueous extracts of |
| 6 | A polyherbal formulation containing extracts of |
| 7 | A polyherbal formulation containing |
| 8 | A polyherbal formulation HP-4® is a combination of 80% alcoholic extract of leaves of |
| 9 | A polyherbal formulation, HD-03® |
| 10 | A polyherbal formulations containing five bioactive fractionated extracts of |
| 11 | A polyherbal formulation containing extracts of |
| 12 | A polyherbal mixture of |
| 13 | A polyherbal Siddha formulation, Karisalai Karpam® |
| 14 | A polyherbal Siddha medicine, Amukkara chooranam® |
| 15 | Ban-zhi-lian |
| 16 | Bazhen decoction |
| 17 | Biherbal formulations of |
| 18 | Chai-Hu-Ching-Kan-Tang® |
| 19 | D-003® |
| 20 | DA-9601®, a quality-controlled extract of |
| 21 | Fengxiang Yigankang® |
| 22 | Fourteen vitex honeys |
| 23 | Gn-3®, a stilbene polymer isolated from |
| 24 | Habb-e-Asgand®, polyherbal Unani formulation |
| 25 | Hepax®, a polyherbal formulation |
| 26 | Himoliv®, a polyherbal formulation |
| 27 | Huanglian-Jie-Du-Tang® |
| 28 | Hwang-hua-mih-tsay ( |
| 29 | IH636 grape seed extract |
| 30 | Karisalai Karpam tablet® |
| 31 | Kava herbal dietary supplements |
| 32 | Liu weiwuling Tablets® |
| 33 | Livartho |
| 34 | Livina®, a polyherbal formulation |
| 35 | Majoon -e-Dabeed-ul-Ward |
| 36 | MAP, a Standardized Herbal Composition, Blend Comprising |
| 37 | Picroliv® |
| 38 | Polyherbal ayurvedic formulations, Liv 52®, Livergen®, Livokin®, Octogen®, Stimuliv®, Triphala® and Tefroliv®, Tritone® (Livosone) |
| 39 | Shekwasha® |
| 40 | Somanathitamrabhasma®, a tamra bhasma preparation containing shudhatamra, parada, gandhaka, haritala and manashila |
| 41 | ‘Teng-khia-u’ |
| 42 | Yang-Gan-Wan |